메뉴 건너뛰기




Volumn 26, Issue 3, 2015, Pages 561-567

TEMHEAD: A single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)

Author keywords

MTOR; PI3KCA; Squamous cell carcinoma of the head and neck; Temsirolimus

Indexed keywords

APITOLISIB; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DIPHENHYDRAMINE; ERLOTINIB; EVEROLIMUS; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; CISPLATIN; RAPAMYCIN;

EID: 84933182955     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu571     Document Type: Article
Times cited : (56)

References (27)
  • 1
    • 0033811339 scopus 로고    scopus 로고
    • Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy
    • Spec No
    • Calais G, Alfonsi M, Bardet E et al. Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy. Bull Cancer 2000; 87 Spec No:48-53.
    • (2000) Bull Cancer , vol.87 , pp. 48-53
    • Calais, G.1    Alfonsi, M.2    Bardet, E.3
  • 2
    • 77954190940 scopus 로고    scopus 로고
    • Human papillomavirus and survival of patients with oropharyngeal cancer
    • Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363(1): 24-35.
    • (2010) N Engl J Med , vol.363 , Issue.1 , pp. 24-35
    • Ang, K.K.1    Harris, J.2    Wheeler, R.3
  • 3
    • 51649085865 scopus 로고    scopus 로고
    • Platinum-based chemotherapy plus cetuximab in head and neck cancer
    • Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116-1127.
    • (2008) N Engl J Med , vol.359 , Issue.11 , pp. 1116-1127
    • Vermorken, J.B.1    Mesia, R.2    Rivera, F.3
  • 4
    • 33750364266 scopus 로고    scopus 로고
    • PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma
    • Kozaki K-I, Imoto I, Pimkhaokham A et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006; 97(12): 1351-1358.
    • (2006) Cancer Sci , vol.97 , Issue.12 , pp. 1351-1358
    • Kozaki, K.-I.1    Imoto, I.2    Pimkhaokham, A.3
  • 5
    • 33645084781 scopus 로고    scopus 로고
    • PIK3CA mutations in head and neck squamous cell carcinoma
    • Qiu W, Schönleben F, Li X et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12(5): 1441-1446.
    • (2006) Clin Cancer Res , vol.12 , Issue.5 , pp. 1441-1446
    • Qiu, W.1    Schönleben, F.2    Li, X.3
  • 6
    • 0036162726 scopus 로고    scopus 로고
    • Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10
    • Poetsch M, Lorenz G, Kleist B. Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet 2002; 132(1): 20-24.
    • (2002) Cancer Genet Cytogenet , vol.132 , Issue.1 , pp. 20-24
    • Poetsch, M.1    Lorenz, G.2    Kleist, B.3
  • 7
    • 45949107072 scopus 로고    scopus 로고
    • Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma
    • Chakraborty S, Mohiyuddin SMA, Gopinath KS, Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 2008; 8: 163.
    • (2008) BMC Cancer , vol.8 , pp. 163
    • Chakraborty, S.1    Mohiyuddin, S.M.A.2    Gopinath, K.S.3    Kumar, A.4
  • 8
    • 77953146127 scopus 로고    scopus 로고
    • Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients
    • Clark C, Shah S, Herman-Ferdinandez L et al. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 2010; 120(6): 1159-1165.
    • (2010) Laryngoscope , vol.120 , Issue.6 , pp. 1159-1165
    • Clark, C.1    Shah, S.2    Herman-Ferdinandez, L.3
  • 9
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
    • (2000) J Natl Cancer Inst , vol.92 , Issue.3 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 10
    • 34548820978 scopus 로고    scopus 로고
    • Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative
    • Molinolo AA, Hewitt SM, Amornphimoltham P et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13(17): 4964-4973.
    • (2007) Clin Cancer Res , vol.13 , Issue.17 , pp. 4964-4973
    • Molinolo, A.A.1    Hewitt, S.M.2    Amornphimoltham, P.3
  • 11
    • 34250180582 scopus 로고    scopus 로고
    • Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
    • Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25 (16): 2171-2177.
    • (2007) J Clin Oncol , vol.25 , Issue.16 , pp. 2171-2177
    • Vermorken, J.B.1    Trigo, J.2    Hitt, R.3
  • 12
    • 79953183347 scopus 로고    scopus 로고
    • Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
    • Machiels J-P, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12 (4): 333-343.
    • (2011) Lancet Oncol , vol.12 , Issue.4 , pp. 333-343
    • Machiels, J.-P.1    Subramanian, S.2    Ruzsa, A.3
  • 13
    • 78649642994 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma
    • Ekshyyan O, Mills GM, Lian T et al. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck 2010; 32(12): 1619-1628.
    • (2010) Head Neck , vol.32 , Issue.12 , pp. 1619-1628
    • Ekshyyan, O.1    Mills, G.M.2    Lian, T.3
  • 14
    • 84875722517 scopus 로고    scopus 로고
    • A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
    • Bauman JE, Arias-Pulido H, Lee S-J et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 2013; 49(5): 461-467.
    • (2013) Oral Oncol , vol.49 , Issue.5 , pp. 461-467
    • Bauman, J.E.1    Arias-Pulido, H.2    Lee, S.-J.3
  • 15
    • 20244365941 scopus 로고    scopus 로고
    • The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
    • Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120(6): 747-759.
    • (2005) Cell , vol.120 , Issue.6 , pp. 747-759
    • Beuvink, I.1    Boulay, A.2    Fumagalli, S.3
  • 16
    • 43749116022 scopus 로고    scopus 로고
    • Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
    • Aissat N, Le Tourneau C, Ghoul A et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62(2): 305-313.
    • (2008) Cancer Chemother Pharmacol , vol.62 , Issue.2 , pp. 305-313
    • Aissat, N.1    Le Tourneau, C.2    Ghoul, A.3
  • 17
    • 84875233075 scopus 로고    scopus 로고
    • Preclinical rational, safety, and preliminary efficacy results of weekly everolimus, carboplatin and paclitaxel as an induction therapy for patients with unresectable locally advanced head & neck squamous cell carcinoma (CAPRA): a GERCOR-IRC phase I/II
    • Faivre S, Dreyer C, Raymond E et al. Preclinical rational, safety, and preliminary efficacy results of weekly everolimus, carboplatin and paclitaxel as an induction therapy for patients with unresectable locally advanced head & neck squamous cell carcinoma (CAPRA): a GERCOR-IRC phase I/II. Ann Oncol 2012: abstr 2897.
    • (2012) Ann Oncol
    • Faivre, S.1    Dreyer, C.2    Raymond, E.3
  • 18
    • 84875978234 scopus 로고    scopus 로고
    • Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway
    • Holsinger FC, Piha-Paul SA, Janku F et al. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol 2013; 31(9): e137-140.
    • (2013) J Clin Oncol , vol.31 , Issue.9 , pp. e137-e140
    • Holsinger, F.C.1    Piha-Paul, S.A.2    Janku, F.3
  • 19
    • 84877584488 scopus 로고    scopus 로고
    • A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    • Fury MG, Sherman E, Ho AL et al. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 2013; 119(10): 1823-1831.
    • (2013) Cancer , vol.119 , Issue.10 , pp. 1823-1831
    • Fury, M.G.1    Sherman, E.2    Ho, A.L.3
  • 20
    • 54549089738 scopus 로고    scopus 로고
    • Hypoxia signalling through mTOR and the unfolded protein response in cancer
    • Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8(11): 851-864.
    • (2008) Nat Rev Cancer , vol.8 , Issue.11 , pp. 851-864
    • Wouters, B.G.1    Koritzinsky, M.2
  • 21
    • 84905698694 scopus 로고    scopus 로고
    • A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients ( pts) after VEGF-targeted therapy (VEGF-TT)
    • Powles T, Oudard S, Escudier B et al. A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients ( pts) after VEGF-targeted therapy (VEGF-TT). J Clin Oncol 2014; 32(s5): abstr 4525.
    • (2014) J Clin Oncol , vol.32 , Issue.SUPPL.5
    • Powles, T.1    Oudard, S.2    Escudier, B.3
  • 22
    • 84880259398 scopus 로고    scopus 로고
    • Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
    • Lui VWY, Hedberg ML, Li H et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013; 3(7): 761-769.
    • (2013) Cancer Discov , vol.3 , Issue.7 , pp. 761-769
    • Lui, V.W.Y.1    Hedberg, M.L.2    Li, H.3
  • 23
    • 17944377486 scopus 로고    scopus 로고
    • Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
    • Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98(18): 10314-10319.
    • (2001) Proc Natl Acad Sci USA , vol.98 , Issue.18 , pp. 10314-10319
    • Neshat, M.S.1    Mellinghoff, I.K.2    Tran, C.3
  • 24
    • 79955068897 scopus 로고    scopus 로고
    • Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway
    • Italiano A, Kind M, Stoeckle E et al. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs 2011; 22(5): 463-467.
    • (2011) Anticancer Drugs , vol.22 , Issue.5 , pp. 463-467
    • Italiano, A.1    Kind, M.2    Stoeckle, E.3
  • 25
    • 84893764401 scopus 로고    scopus 로고
    • Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
    • Mackay HJ, Eisenhauer EA, Kamel-Reid S et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 2014; 120(4): 603-610.
    • (2014) Cancer , vol.120 , Issue.4 , pp. 603-610
    • Mackay, H.J.1    Eisenhauer, E.A.2    Kamel-Reid, S.3
  • 26
    • 84898732516 scopus 로고    scopus 로고
    • Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy
    • Voss MH, Hakimi AA, Pham CG et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 2014; 20: 1955-64.
    • (2014) Clin Cancer Res , vol.20 , pp. 1955-1964
    • Voss, M.H.1    Hakimi, A.A.2    Pham, C.G.3
  • 27
    • 84874285876 scopus 로고    scopus 로고
    • Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie
    • Knoedler M, Gauler TC, Gruenwald V et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology 2013; 84(5): 284-289.
    • (2013) Oncology , vol.84 , Issue.5 , pp. 284-289
    • Knoedler, M.1    Gauler, T.C.2    Gruenwald, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.